RSQ-15(RSQ-15) - 药物靶点：ELF3_专利_临床

概要

基本信息

药物类型

DNA疫苗、预防性疫苗

别名

esx gene family targeting multivalent DNA vaccine (Inovio)

靶点

ELF3

作用方式

调节剂

作用机制

ESX基因调节剂

治疗领域

感染

在研适应症-

非在研适应症

结核

原研机构

Inovio Pharmaceuticals, Inc.

在研机构-

非在研机构

Inovio Pharmaceuticals, Inc.

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 RSQ-15 相关的临床结果

登录后查看更多信息

100 项与 RSQ-15 相关的转化医学

登录后查看更多信息

100 项与 RSQ-15 相关的专利（医药）

登录后查看更多信息

1

项与 RSQ-15 相关的文献（医药）

2019-07-19·Microbiology Spectrum2区 · 生物学

ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins

2区 · 生物学

Review

作者: Brosch, Roland ; Vaziri, Farzam

ABSTRACT The causative agent of human tuberculosis, Mycobacterium tuberculosis , has a complex lipid-rich diderm envelope, which acts as a major barrier protecting the bacterium against the hostile environment inside the host cells. For the transfer of diverse molecules across this complex cell envelope, M. tuberculosis has a series of general and specialized protein secretion systems, characterized by the SecA general secretion pathway, the twin-arginine translocation pathway, and five specific ESX type VII secretion systems. In this review, we focus on the latter systems, known as ESX-1 to ESX-5, which were first discovered almost 20 years ago during the in silico analysis of the genome sequence of M. tuberculosis H37Rv. Since then, these systems have been the subject of highly dynamic research due to their involvement in several key biological processes and host-pathogen interactions of the tubercle bacilli.

100 项与 RSQ-15 相关的药物交易

登录后查看更多信息